S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors|
|Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe|
|Nektar Presents Preclinical Study Findings for Etirinotecan Pegol (NKTR-102) in Combination with a PARP Inhibitor in BRCA1-deficient Cancer Model|
|Three New Myriad Studies Highlighted at 2014 San Antonio Breast Cancer Symposium|
|Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM)|
|Myriad Receives FDA Approval of BRACAnalysis CDx(TM) as Companion Diagnostic for Lynparza(TM) (olaparib) in Ovarian Cancer Patients|
|Myriad Genetics Reports Fiscal First Quarter 2015 Financial Results|
|Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients|
|Nektar Therapeutics Reports Financial Results for the Third Quarter of 2014|
|Karyopharm Presents Data on Oncology Pipeline at EORTC-NCI-AACR Annual Meeting|
Click above to view more mutual fund data and stats for parp - Groupe Partouche.